



Umpqua Health Alliance (OHP) Formulary Changes
April 2018

Umpqua Health Alliance would like to advise you of the following currently monthly changes that have been made to the Umpqua Health Alliance Formulary.

Any changes seen below will also be reflected on our latest version of our print formulary which can be located on our website (www.umpquahealth.com) under the members or providers tab.

Formulary Change	
Medication	Limitations/Changes
buprenorphine/naloxone SL tablets	Removed PA requirements. Still must follow Suboxone/buprenorphine policy.
levalbuterol HFA inhaler	Removed PA requirements.
polyethylene glycol 3350 powder packets	Removed from formulary.
QVAR Redihaler	Added to formulary without PA Requirements.
amlodipine/valsartan/HCTZ	Added PA requirements.
Oral Contraceptives	Removed step therapy requirements from formulary. However, some formulations now require PA instead, please see print formulary for further information on specific drugs.

If your office has questions about these changes, please contact:

Sara Hrouda, CPhT @ 541-229-8901 or shrouda@umpquahealth.com

Kim Karlovich, CPhT @ 541-229-8902 or kkarlovich@umpquahealth.com

Jamie Vanassche CPhT @ 541-229-7002 or jvanassche@umpquahealth.com